Veloxis Pharmaceuticals Inc.

États‑Unis d’Amérique

Retour au propriétaire

1-41 de 41 pour Veloxis Pharmaceuticals Inc. Trier par
Recheche Texte
Affiner par
Type PI
        Marque 22
        Brevet 19
Juridiction
        États-Unis 28
        International 7
        Europe 3
        Canada 3
Date
2025 (AACJ) 1
2023 3
2022 2
2021 2
2020 1
Voir plus
Classe IPC
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine 16
A61K 9/20 - Pilules, pastilles ou comprimés 16
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier 9
A61K 9/16 - AgglomérésGranulésMicrobilles 6
A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol 5
Voir plus
Classe NICE
05 - Produits pharmaceutiques, vétérinaires et hygièniques 22
42 - Services scientifiques, technologiques et industriels, recherche et conception 19
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture. 17
40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau 14
41 - Éducation, divertissements, activités sportives et culturelles 8
Voir plus
Statut
En Instance 2
Enregistré / En vigueur 39

1.

TACROLIMUS FOR IMPROVED TREATMENT OF TRANSPLANT PATIENTS

      
Numéro d'application 18799080
Statut En instance
Date de dépôt 2024-08-09
Date de la première publication 2025-04-17
Propriétaire Veloxis Pharmaceuticals, Inc. (USA)
Inventeur(s)
  • Gordon, Robert D.
  • Holm, Per
  • Lademann, Anne-Marie
  • Norling, Tomas

Abrégé

An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.

Classes IPC  ?

  • A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
  • A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
  • A61K 9/16 - AgglomérésGranulésMicrobilles
  • A61K 9/20 - Pilules, pastilles ou comprimés
  • A61K 9/28 - DragéesPilules ou comprimés avec revêtements
  • A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat
  • A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE

2.

Stabilized tacrolimus composition

      
Numéro d'application 17857442
Numéro de brevet 12403095
Statut Délivré - en vigueur
Date de dépôt 2022-07-05
Date de la première publication 2023-03-30
Date d'octroi 2025-09-02
Propriétaire VELOXIS PHARMACEUTICALS, INC. (USA)
Inventeur(s)
  • Skak, Nikolaj
  • Holm, Per

Abrégé

The invention relates to a stable pharmaceutical composition comprising comprising a solid dispersion of tacrolimus in a vehicle further comprising e stabilizing agent capable of providing a pH below 7 in the composition, as measured after re-dispersion in water, and preventing or reducing the formation upon storage of major degradation products of tacrolimus, in particular the 8-epitacrolimus.

Classes IPC  ?

  • A61K 9/20 - Pilules, pastilles ou comprimés
  • A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
  • A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine

3.

VELOXIS

      
Numéro de série 97753205
Statut En instance
Date de dépôt 2023-01-13
Propriétaire Veloxis Pharmaceuticals, Inc. ()
Classes de Nice  ?
  • 05 - Produits pharmaceutiques, vétérinaires et hygièniques
  • 41 - Éducation, divertissements, activités sportives et culturelles
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.

Produits et services

Pharmaceutical preparations, namely, immunotherapeutic and immunosuppressive preparations for medical use for treatment of transplant patients; pharmaceutical preparations and drug delivery systems, pharmaceutical modified release systems, and pharmaceutical controlled release systems, comprised of tablets, granules, pills, sachets, powders, capsules, solutions or fluids, all of the above for use in the treatment of physical disorders, emergencies and traumas, burns, diseases of the heart and blood vessels, neurological diseases, and cancer Education and training services, namely, arranging and conducting of seminars, workshops, conferences, lectures and congresses, all in the medical, chemical and pharmaceutical fields Scientific and technological services, namely, scientific research, analysis and testing in the field of medical science, pharmacology, biotechnology and bacteriological areas and providing consultation and information relating thereto; design of drug delivery systems for medical use; conducting of tests regarding medical applications; packaging design for others; designing and development of medical equipment; designing pharmaceutical medical preparations; development of pharmaceutical formulations; design and development of granulation technology and tablet technology and providing consultation and information thereto; materials testing for the pharmaceutical and medical industries Medical and pharmaceutical assistance and consultation, namely, medical and pharmaceutical information services, namely, providing medical and scientific research information in the field of pharmaceuticals

4.

VELOXIS

      
Numéro d'application 018821255
Statut Enregistrée
Date de dépôt 2023-01-11
Date d'enregistrement 2023-05-23
Propriétaire Veloxis Pharmaceuticals, Inc. (USA)
Classes de Nice  ?
  • 05 - Produits pharmaceutiques, vétérinaires et hygièniques
  • 41 - Éducation, divertissements, activités sportives et culturelles
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.

Produits et services

Pharmaceutical preparations, namely, immunotherapeutic and immunosuppressive preparations for medical use for treatment of transplant patients; pharmaceutical preparations and drug delivery systems, pharmaceutical modified release systems, and pharmaceutical controlled release systems, comprised of tablets, granules, pills, sachets, powders, capsules, solutions or fluids, all of the above for use in the treatment of physical disorders, emergencies and traumas, burns, diseases of the heart and blood vessels, neurological diseases, and cancer. Education and training services, namely, arranging and conducting of seminars, workshops, conferences, lectures and congresses, all in the medical, chemical and pharmaceutical fields. Scientific and technological services, namely, scientific research, analysis and testing in the field of medical science, pharmacology, biotechnology and bacteriological areas and providing consultation and information relating thereto; design of drug delivery systems for medical use; conducting of tests regarding medical applications; packaging design for others; designing and development of medical equipment; designing pharmaceutical medical preparations; development of pharmaceutical formulations; design and development of granulation technology and tablet technology and providing consultation and information thereto; materials testing for the pharmaceutical and medical industries. Medical and pharmaceutical assistance and consultation, namely, medical and pharmaceutical information services, namely, providing medical and scientific research information in the field of pharmaceuticals.

5.

Regimen for suppressing organ rejection

      
Numéro d'application 17447581
Numéro de brevet 11957666
Statut Délivré - en vigueur
Date de dépôt 2021-09-14
Date de la première publication 2022-08-11
Date d'octroi 2024-04-16
Propriétaire VELOXIS PHARMACEUTICALS INC. (USA)
Inventeur(s) Polvino, William J.

Abrégé

max than an immediate release formulation of tacrolimus while providing the same or greater area under the curve (AUC), (iii) releases the tacrolimus substantially in the colon and/or the lower ileum, (iv) releases at most 63.5% of the tacrolimus in the dosage form at the 12 hour time point, or (v) any combination of any of the foregoing.

Classes IPC  ?

  • A61K 31/435 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle
  • A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
  • A61K 9/20 - Pilules, pastilles ou comprimés
  • A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
  • A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
  • A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
  • A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
  • A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
  • A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

6.

Tacrolimus for improved treatment of transplant patients

      
Numéro d'application 17444402
Numéro de brevet 12083103
Statut Délivré - en vigueur
Date de dépôt 2021-08-04
Date de la première publication 2022-06-23
Date d'octroi 2024-09-10
Propriétaire VELOXIS PHARMACEUTICALS, INC. (USA)
Inventeur(s)
  • Gordon, Robert D.
  • Holm, Per
  • Lademann, Anne-Marie
  • Norling, Tomas

Abrégé

An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.

Classes IPC  ?

  • A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
  • A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
  • A61K 9/16 - AgglomérésGranulésMicrobilles
  • A61K 9/20 - Pilules, pastilles ou comprimés
  • A61K 9/28 - DragéesPilules ou comprimés avec revêtements
  • A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat
  • A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE

7.

Tacrolimus for improved treatment of transplant patients

      
Numéro d'application 17085379
Numéro de brevet 11123331
Statut Délivré - en vigueur
Date de dépôt 2020-10-30
Date de la première publication 2021-02-18
Date d'octroi 2021-09-21
Propriétaire VELOXIS PHARMACEUTICALS INC. (USA)
Inventeur(s)
  • Gordon, Robert D.
  • Holm, Per
  • Lademann, Anne-Marie
  • Norling, Tomas

Abrégé

An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.

Classes IPC  ?

  • A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
  • A61K 9/20 - Pilules, pastilles ou comprimés
  • A61K 9/28 - DragéesPilules ou comprimés avec revêtements
  • A61K 9/16 - AgglomérésGranulésMicrobilles
  • A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat
  • A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
  • A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE

8.

Tacrolimus for improved treatment of transplant patients

      
Numéro d'application 17085291
Numéro de brevet 11110081
Statut Délivré - en vigueur
Date de dépôt 2020-10-30
Date de la première publication 2021-02-18
Date d'octroi 2021-09-07
Propriétaire VELOXIS PHARMACEUTICALS INC. (USA)
Inventeur(s)
  • Gordon, Robert D.
  • Holm, Per
  • Lademann, Anne-Marie
  • Norling, Tomas

Abrégé

An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.

Classes IPC  ?

  • A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
  • A61K 9/20 - Pilules, pastilles ou comprimés
  • A61K 9/28 - DragéesPilules ou comprimés avec revêtements
  • A61K 9/16 - AgglomérésGranulésMicrobilles
  • A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat
  • A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
  • A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE

9.

Regimen for suppressing organ rejection

      
Numéro d'application 16678527
Numéro de brevet 11141408
Statut Délivré - en vigueur
Date de dépôt 2019-11-08
Date de la première publication 2020-08-27
Date d'octroi 2021-10-12
Propriétaire VELOXIS PHARMACEUTICALS INC. (USA)
Inventeur(s) Polvino, William J.

Abrégé

max than an immediate release formulation of tacrolimus while providing the same or greater area under the curve (AUC), (iii) releases the tacrolimus substantially in the colon and/or the lower ileum, (iv) releases at most 63.5% of the tacrolimus in the dosage form at the 12 hour time point, or (v) any combination of any of the foregoing.

Classes IPC  ?

  • A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
  • A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
  • A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
  • A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
  • A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
  • A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
  • A61K 9/20 - Pilules, pastilles ou comprimés
  • A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier

10.

Stabilized tacrolimus composition

      
Numéro d'application 16188805
Numéro de brevet 11419823
Statut Délivré - en vigueur
Date de dépôt 2018-11-13
Date de la première publication 2019-09-19
Date d'octroi 2022-08-23
Propriétaire VELOXIS PHARMACEUTICALS INC. (USA)
Inventeur(s)
  • Skak, Nikolaj
  • Holm, Per

Abrégé

The invention relates to a stable pharmaceutical composition comprising comprising a solid dispersion of tacrolimus in a vehicle further comprising a stabilizing agent capable of providing a pH below 7 in the composition, as measured after re-dispersion in water, and preventing or reducing the formation upon storage of major degradation products of tacrolimus, in particular the 8-epitacrolimus.

Classes IPC  ?

  • A61K 9/20 - Pilules, pastilles ou comprimés
  • A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
  • A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine

11.

Regimen for suppressing organ rejection

      
Numéro d'application 15682275
Numéro de brevet 10485793
Statut Délivré - en vigueur
Date de dépôt 2017-08-21
Date de la première publication 2018-07-12
Date d'octroi 2019-11-26
Propriétaire VELOXIS PHARMACEUTICALS INC. (USA)
Inventeur(s) Polvino, William J.

Abrégé

max than an immediate release formulation of tacrolimus while providing the same or greater area under the curve (AUC), (iii) releases the tacrolimus substantially in the colon and/or the lower ileum, (iv) releases at most 63.5% of the tacrolimus in the dosage form at the 12 hour time point, or (v) any combination of any of the foregoing.

Classes IPC  ?

  • A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
  • A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
  • A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
  • A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
  • A61K 9/20 - Pilules, pastilles ou comprimés
  • A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
  • A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
  • A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

12.

MELTDOSE

      
Numéro d'application 186929000
Statut Enregistrée
Date de dépôt 2017-11-22
Date d'enregistrement 2020-10-09
Propriétaire VELOXIS PHARMACEUTICALS, INC. (USA)
Classes de Nice  ?
  • 05 - Produits pharmaceutiques, vétérinaires et hygièniques
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception

Produits et services

(1) Pharmaceutical preparations, namely, immunotherapeutic and immunosuppressive preparations for medical use for treatment of transplantation patients; medical preparations and drug delivery systems, pharmaceutical modified release systems, and controlled release systems, comprised of tablets, granules, pills, sachets, powders, capsules, all of the above for use in the treatment of cholesterol related diseases, allergy, burns, diseases of the heart and blood vessels, dental and gum diseases, diabetes, diseases and afflictions of the gastroenterological system, cancer, ophthalmological diseases, pulmonological diseases and afflictions, rheumatism, urological diseases and afflictions and generalized pain. (1) Development of drug delivery systems for others, namely, development of solid dosage forms, pharmaceutical controlled release systems, modified release systems and pharmaceutical modified release systems and consultation related thereto.

13.

MELTDOSE

      
Numéro de série 87631924
Statut Enregistrée
Date de dépôt 2017-10-03
Date d'enregistrement 2020-01-28
Propriétaire VELOXIS PHARMACEUTICALS, INC. ()
Classes de Nice  ? 05 - Produits pharmaceutiques, vétérinaires et hygièniques

Produits et services

Pharmaceutical preparations, namely, immunotherapeutic and immunosuppressive preparations for medical use for treatment of transplantation patients; medical preparations and pharmaceutical preparations, namely, drug delivery systems and drug modified systems comprising tablets, granules, pills, sachets, powders, capsules for controlled release of low water soluble and insoluble drugs, all of the above for use in the treatment of cholesterol related diseases, mental and physical disorders, traumas and emergencies, addictions, aging, allergy and immunology, burns, diseases of the heart and blood vessels, dental and gum diseases, skin diseases, nutritional and dietary diseases, diseases of the endocrinological system and pancreatic diseases, diabetes, epidemical diseases, diseases and afflictions of the gastroenterological system, diseases of the blood, infectious diseases, neurological diseases, nephrological diseases, diseases in the obstetrical and gynecological field, cancer, ophthalmological diseases, diseases and afflictions affecting the bones, joints, cartilage material and muscles, diseases and afflictions of the ear, nose and throat, diseases and afflictions in the psychiatric field, pulmonological diseases and afflictions, rheumatism, urological diseases and afflictions and generalized pain

14.

Stabilized tacrolimus composition

      
Numéro d'application 15405879
Numéro de brevet 10166190
Statut Délivré - en vigueur
Date de dépôt 2017-01-13
Date de la première publication 2017-05-04
Date d'octroi 2019-01-01
Propriétaire VELOXIS PHARMACEUTICALS INC. (USA)
Inventeur(s)
  • Skak, Nikolaj
  • Holm, Per

Abrégé

The invention relates to a stable pharmaceutical composition comprising comprising a solid dispersion of tacrolimus in a vehicle further comprising a stabilizing agent capable of providing a pH below 7 in the composition, as measured after re-dispersion in water, and preventing or reducing the formation upon storage of major degradation products of tacrolimus, in particular the 8-epitacrolimus.

Classes IPC  ?

  • A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
  • A61K 9/20 - Pilules, pastilles ou comprimés
  • A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine

15.

Tacrolimus for improved treatment of transplant patients

      
Numéro d'application 15041986
Numéro de brevet 10864199
Statut Délivré - en vigueur
Date de dépôt 2016-02-11
Date de la première publication 2016-08-25
Date d'octroi 2020-12-15
Propriétaire VELOXIS PHARMACEUTICALS INC. (USA)
Inventeur(s)
  • Gordon, Robert D.
  • Holm, Per
  • Lademann, Anne-Marie
  • Norling, Tomas

Abrégé

An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.

Classes IPC  ?

  • A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
  • A61K 9/20 - Pilules, pastilles ou comprimés
  • A61K 9/28 - DragéesPilules ou comprimés avec revêtements
  • A61K 9/16 - AgglomérésGranulésMicrobilles
  • A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat
  • A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
  • A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE

16.

Regimen for supressing organ rejection

      
Numéro d'application 14867773
Numéro de brevet 09775834
Statut Délivré - en vigueur
Date de dépôt 2015-09-28
Date de la première publication 2016-01-21
Date d'octroi 2017-10-03
Propriétaire VELOXIS PHARMACEUTICALS INC. (USA)
Inventeur(s) Polvino, William J.

Abrégé

max than an immediate release formulation of tacrolimus while providing the same or greater area under the curve (AUC), (iii) releases the tacrolimus substantially in the colon and/or the lower ileum, (iv) releases at most 63.5% of the tacrolimus in the dosage form at the 12 hour time point, or (v) any combination of any of the foregoing.

Classes IPC  ?

  • A61K 31/44 - Pyridines non condenséesLeurs dérivés hydrogénés
  • A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
  • A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
  • A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
  • A61K 9/20 - Pilules, pastilles ou comprimés
  • A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
  • A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
  • A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

17.

Envarsus XR

      
Numéro d'application 1246622
Statut Enregistrée
Date de dépôt 2014-10-16
Date d'enregistrement 2014-10-16
Propriétaire Veloxis Pharmaceuticals, Inc. (USA)
Classes de Nice  ?
  • 05 - Produits pharmaceutiques, vétérinaires et hygièniques
  • 40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.

Produits et services

Pharmaceutical preparations, including immunotherapeutic and immunosuppressive preparations for medical use for treatment of transplantation patients; medical preparations and drug delivery systems, pharmaceutical modified release systems, and controlled release systems, comprised of tablets, granules, pills, sachets, powders, capsules, all of the above i.a. for use in the treatment of mental and physical disorders, traumas and emergencies, addictions, aging, allergy/immunology, burns, diseases of the heart and blood vessels, dental and gum diseases, skin diseases, nutritional and dietary diseases, diseases of the endocrinological system and pancreatic diseases, diabetes, epidemical diseases, diseases and afflictions of the gastroenterological system, diseases of the blood, infectious diseases, neurological diseases, nephrological diseases, diseases in the obstetrical and gynaecological field, cancer, ophthalmological diseases, diseases and afflictions affecting the bones, joints, cartilage material and muscles, diseases and afflictions of the ear, nose and throat, diseases and afflictions in the psychiatric field, pulmonological diseases and afflictions, rheumatism, urological diseases and afflictions and generalised pain; veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. Treatment of materials, namely milling, grinding, mixing, compressing, and melting of pharmaceutical, medicinal, biotechnical and bacteriological substances, preparations, formulations and solutions, for use in the pharmaceutical and medical industries. Scientific and technological services as well as research and design in connection therewith, including within the medical, pharmaceutical, biotechnical and bacteriological areas and providing consultation and information relating thereto; conducting of tests regarding medical applications; packaging design for others; designing and development of medical equipment; designing pharmaceutical medical preparations; development of pharmaceutical formulations; design and development of granulation technology and tablet technology and providing consultation and information thereto; materials testing for the pharmaceutical and medical industries; industrial analysis and research; design and development of computer hardware and computer software. Medical services; medical and pharmaceutical assistance and consultation; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.

18.

Miscellaneous Design

      
Numéro d'application 1246623
Statut Enregistrée
Date de dépôt 2014-10-16
Date d'enregistrement 2014-10-16
Propriétaire Veloxis Pharmaceuticals, Inc. (USA)
Classes de Nice  ?
  • 05 - Produits pharmaceutiques, vétérinaires et hygièniques
  • 40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.

Produits et services

Pharmaceutical preparations, including immunotherapeutic and immunosuppressive preparations for medical use for treatment of transplantation patients; medical preparations and drug delivery systems, pharmaceutical modified release systems, and controlled release systems, comprised of tablets, granules, pills, sachets, powders, capsules, all of the above i.a. for use in the treatment of mental and physical disorders, traumas and emergencies, addictions, aging, allergy/immunology, burns, diseases of the heart and blood vessels, dental and gum diseases, skin diseases, nutritional and dietary diseases, diseases of the endocrinological system and pancreatic diseases, diabetes, epidemical diseases, diseases and afflictions of the gastroenterological system, diseases of the blood, infectious diseases, neurological diseases, nephrological diseases, diseases in the obstetrical and gynaecological field, cancer, ophthalmological diseases, diseases and afflictions affecting the bones, joints, cartilage material and muscles, diseases and afflictions of the ear, nose and throat, diseases and afflictions in the psychiatric field, pulmonological diseases and afflictions, rheumatism, urological diseases and afflictions and generalised pain; veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. Treatment of materials, namely milling, grinding, mixing, compressing, and melting of pharmaceutical, medicinal, biotechnical and bacteriological substances, preparations, formulations and solutions, for use in the pharmaceutical and medical industries. Scientific and technological services as well as research and design in connection therewith, including within the medical, pharmaceutical, biotechnical and bacteriological areas and providing consultation and information relating thereto; conducting of tests regarding medical applications; packaging design for others; designing and development of medical equipment; designing pharmaceutical medical preparations; development of pharmaceutical formulations; design and development of granulation technology and tablet technology and providing consultation and information thereto; materials testing for the pharmaceutical and medical industries; industrial analysis and research; design and development of computer hardware and computer software. Medical services; medical and pharmaceutical assistance and consultation; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.

19.

ENVARSUS XR

      
Numéro d'application 171047400
Statut Enregistrée
Date de dépôt 2015-01-08
Date d'enregistrement 2019-07-03
Propriétaire VELOXIS PHARMACEUTICALS, INC. (USA)
Classes de Nice  ?
  • 05 - Produits pharmaceutiques, vétérinaires et hygièniques
  • 40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.

Produits et services

(1) Pharmaceutical preparations, namely, an immunotherapeutic and immunosuppressive preparation indicated for the prophylaxis of organ rejection in transplant patients converted from tacrolimus immediate-release formulations in combination with other immune-suppressants, in the form of a pharmaceutical modified and controlled release system, comprised of tablets, granules, pills, sachets, powders, or capsules. (2) Medical preparations and drug delivery systems, pharmaceutical modified release systems, and controlled release systems, namely, medical formulations delivered in the form of tablets, granules, pills, sachets, powders, capsules, which allow for modified timed release, controlled timed release and targeted release of the formulations, all of the above for use in the treatment of allergy and immunology, namely, autoimmune diseases, immunologic deficiency syndrome; medical preparations and drug delivery systems, pharmaceutical modified release systems, and controlled release systems, namely, medical formulations delivered in the form of tablets, granules, pills, sachets, powders, capsules, which allow for modified timed release, controlled timed release and targeted release of the formulations, all of the above for use in the treatment of nephrological diseases, namely, polycystic kidney disease, acute kidney failure, hypertension. (1) Treatment of materials, namely, milling, grinding, mixing, compressing, and melting of pharmaceutical, medicinal, biotechnical and bacteriological substances, preparations, formulations and solutions, for use in the pharmaceutical and medical industries. (2) Scientific and technological services, namely, conducting clinical testing and providing research design in the field of clinical trials within the medical, pharmaceutical, biotechnical and bacteriological areas; providing scientific consultation and information in the pharmaceutical, biotechnical and bacteriological fields and providing scientific consultation and information in the medical field relating to pharmaceutical drug delivery systems and immunologic practices to assist in transplant situations. (3) Packaging design for others. (4) Designing and development of medical equipment. (5) Designing pharmaceutical medical preparations; development of pharmaceutical formulations; design and development of granular technology and tablet technology, namely, drug delivery in the form of tablets and pills. (6) Materials testing for the pharmaceutical and medical industries. (7) Medical services, namely, medical and pharmaceutical assistance and consultation, namely, medical and pharmaceutical information services, namely, providing medical and scientific research information in the field of pharmaceuticals.

20.

ENVARSUS

      
Numéro d'application 171047500
Statut Enregistrée
Date de dépôt 2015-01-08
Date d'enregistrement 2019-07-03
Propriétaire VELOXIS PHARMACEUTICALS, INC. (USA)
Classes de Nice  ?
  • 05 - Produits pharmaceutiques, vétérinaires et hygièniques
  • 40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.

Produits et services

(1) Pharmaceutical preparations, namely, an immunotherapeutic and immunosuppressive preparation indicated for the prophylaxis of organ rejection in transplant patients converted from tacrolimus immediate-release formulations in combination with other immune-suppressants, in the form of a pharmaceutical modified and controlled release system, comprised of tablets, granules, pills, sachets, powders, or capsules. (2) Medical preparations and drug delivery systems, pharmaceutical modified release systems, and controlled release systems, namely, medical formulations delivered in the form of tablets, granules, pills, sachets, powders, capsules, which allow for modified timed release, controlled timed release and targeted release of the formulations, all of the above for use in the treatment of allergy and immunology, namely, autoimmune diseases, immunologic deficiency syndrome; medical preparations and drug delivery systems, pharmaceutical modified release systems, and controlled release systems, namely, medical formulations delivered in the form of tablets, granules, pills, sachets, powders, capsules, which allow for modified timed release, controlled timed release and targeted release of the formulations, all of the above for use in the treatment of nephrological diseases, namely, polycystic kidney disease, acute kidney failure, hypertension. (1) Treatment of materials, namely, milling, grinding, mixing, compressing, and melting of pharmaceutical, medicinal, biotechnical and bacteriological substances, preparations, formulations and solutions, for use in the pharmaceutical and medical industries. (2) Scientific and technological services, namely, conducting clinical testing and providing research design in the field of clinical trials within the medical, pharmaceutical, biotechnical and bacteriological areas; providing scientific consultation and information in the pharmaceutical, biotechnical and bacteriological fields and providing scientific consultation and information in the medical field relating to pharmaceutical drug delivery systems and immunologic practices to assist in transplant situations. (3) Packaging design for others. (4) Designing and development of medical equipment. (5) Designing pharmaceutical medical preparations; development of pharmaceutical formulations; design and development of granular technology and tablet technology, namely, drug delivery in the form of tablets and pills. (6) Materials testing for the pharmaceutical and medical industries. (7) Medical services, namely, medical and pharmaceutical assistance and consultation, namely, medical and pharmaceutical information services, namely, providing medical and scientific research information in the field of pharmaceuticals.

21.

Regimen for suppressing organ rejection

      
Numéro d'application 14317500
Numéro de brevet 09168246
Statut Délivré - en vigueur
Date de dépôt 2014-06-27
Date de la première publication 2015-01-01
Date d'octroi 2015-10-27
Propriétaire VELOXIS PHARMACEUTICALS INC. (USA)
Inventeur(s) Polvino, William J.

Abrégé

max than an immediate release formulation of tacrolimus while providing the same or greater area under the curve (AUC), (iii) releases the tacrolimus substantially in the colon and/or the lower ileum, (iv) releases at most 63.5% of the tacrolimus in the dosage form at the 12 hour time point, or (v) any combination of any of the foregoing.

Classes IPC  ?

  • A61K 31/44 - Pyridines non condenséesLeurs dérivés hydrogénés
  • A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
  • A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
  • A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
  • A61K 9/20 - Pilules, pastilles ou comprimés
  • A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

22.

ENVARSUS XR

      
Numéro de série 79165003
Statut Enregistrée
Date de dépôt 2014-10-16
Date d'enregistrement 2015-10-27
Propriétaire Veloxis Pharmaceuticals, Inc. (USA)
Classes de Nice  ?
  • 40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
  • 05 - Produits pharmaceutiques, vétérinaires et hygièniques
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.

Produits et services

[ Treatment of materials, namely, milling, grinding, mixing, compressing, and melting of pharmaceutical, medicinal, bio technical and bacteriological substances, preparations, formulations and solutions, for use in the pharmaceutical and medical industries ] Pharmaceutical preparations, namely, immunotherapeutic and immunosuppressive preparations for medical use for treatment of transplantation patients; medical preparations and drug delivery systems, pharmaceutical modified release systems, and controlled release systems, comprised of tablets, [ granules, ] pills [, sachets, powders, capsules, all of the above ] for use in the treatment of [ mental and physical disorders, traumas and emergencies, addictions, aging, allergy, ] immunology, [ burns, ] diseases of the heart and blood vessels, [ dental and gum diseases, skin diseases, nutritional and dietary diseases, ] diseases of the endocrinological system and pancreatic diseases, [ diabetes, epidemical diseases, diseases and afflictions of the gastroenterological system, diseases of the blood, infectious diseases, ] neurological diseases, nephrological diseases, [ diseases in the obstetrical and gynaecological field, cancer, ophthalmological diseases, diseases and afflictions affecting the bones, joints, cartilage material and muscles, diseases and afflictions of the ear, nose and threat, diseases and afflictions in the psychiatric field, ] pulmonological diseases [ and afflictions, rheumatism, urological diseases and afflictions and generalized pain ] [ Scientific and technological services, namely, clinical testing and technology transfer services as well as research and design in connection therewith, namely, within the medical, pharmaceutical, bio technical and bacteriological areas and providing scientific consultation and information relating thereto; conducting of tests regarding medical applications; packaging design for others; designing and development of medical equipment; designing pharmaceutical medical preparations; development of pharmaceutical formulations; design and development of granulation technology and tablet technology and providing consultation and information thereto; materials testing for the pharmaceutical and medical industries ] [ Medical services; medical and pharmaceutical assistance and consultation, namely, medical and pharmaceutical information services, namely, providing medical and scientific research information in the field of pharmaceuticals ]

23.

Miscellaneous Design

      
Numéro de série 79165004
Statut Enregistrée
Date de dépôt 2014-10-16
Date d'enregistrement 2015-10-27
Propriétaire Veloxis Pharmaceuticals, Inc. ()
Classes de Nice  ?
  • 40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
  • 05 - Produits pharmaceutiques, vétérinaires et hygièniques
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.

Produits et services

[ Treatment of materials, namely, milling, grinding, mixing, compressing, and melting of pharmaceutical, medicinal, biotechnical and bacteriological substances, preparations, formulations and solutions, for use in the pharmaceutical and medical industries ] Pharmaceutical preparations, namely, immunotherapeutic and immunosuppressive preparations for medical use for treatment of transplantation patients; medical preparations and drug delivery systems, pharmaceutical modified release systems, and controlled release systems, comprised of tablets, [ granules, ] pills, [ sachets, powders, capsules, all of the above ] for use in the treatment of [ mental and physical disorders, traumas and emergencies, addictions, aging, allergy, ] immunology, [ burns, ] diseases of the heart and blood vessels, [ dental and gum diseases, skin diseases, nutritional and dietary diseases, ] diseases of the endocrinological system and pancreatic diseases, [ diabetes, epidemical diseases, diseases and afflictions of the gastroenterological system, diseases of the blood, infectious diseases, ] neurological diseases, nephrological diseases, [ diseases in the obstetrical and gynaecological field, cancer, ophthalmological diseases, diseases and afflictions affecting the bones, joints, cartilage material and muscles, diseases and afflictions of the ear, nose and throat, diseases and afflictions in the psychiatric field, ] pulmonological diseases [ and afflictions, rheumatism, urological diseases and afflictions and generalised pain ] [ Scientific and technological services, namely, clinical testing and technology transfer services as well as research and design in connection therewith, namely, within the medical, pharmaceutical, biotechnical and bacteriological areas and providing scientific consultation and information relating thereto; conducting of tests regarding medical applications; packaging design for others; designing and development of medical equipment; designing pharmaceutical medical preparations; development of pharmaceutical formulations; design and development of granulation technology and tablet technology and providing consultation and information thereto; materials testing for the pharmaceutical and medical industries ] [ Medical services; medical and pharmaceutical assistance and consultation, namely, medical and pharmaceutical information services, namely, providing medical and scientific research information in the field of pharmaceuticals ]

24.

ENVARSUS XR

      
Numéro de série 86270008
Statut Enregistrée
Date de dépôt 2014-05-02
Date d'enregistrement 2016-01-19
Propriétaire VELOXIS PHARMACEUTICALS, INC. ()
Classes de Nice  ?
  • 05 - Produits pharmaceutiques, vétérinaires et hygièniques
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.

Produits et services

Pharmaceutical preparations, namely, immunotherapeutic and immunosuppressive preparations for medical use for treatment of transplantation patients; medical preparations and drug delivery systems, pharmaceutical modified release systems, and controlled release systems, comprised of tablets, [ granules, ] pills, [ sachets, powders, capsules, all of the above ] for use in the treatment of [ mental and physical disorders, traumas and emergencies, addictions, aging, allergy and ] immunology, [ burns, ] diseases of the heart and blood vessels, [ dental and gum diseases, skin diseases, nutritional and dietary diseases, ] diseases of the endocrinological system and pancreatic diseases, [ diabetes, epidemical diseases, diseases and afflictions of the gastroenterological system, diseases of the blood, infectious diseases, ] neurological diseases, nephrological diseases, [ diseases in the obstetrical and gynecological field, cancer, ophthalmological diseases, diseases and afflictions affecting the bones, joints, cartilage material and muscles, diseases and afflictions of the ear, nose and throat, diseases and afflictions in the psychiatric field, ] pulmonological diseases [ and afflictions, rheumatism, urological diseases and afflictions and generalised pain ] [ Medical services ]

25.

Stabilized tacrolimus composition

      
Numéro d'application 13029304
Numéro de brevet 09549918
Statut Délivré - en vigueur
Date de dépôt 2011-02-17
Date de la première publication 2014-02-06
Date d'octroi 2017-01-24
Propriétaire VELOXIS PHARMACEUTICALS INC. (USA)
Inventeur(s)
  • Skak, Nikolaj
  • Holm, Per

Abrégé

The invention relates to a stable pharmaceutical composition comprising comprising a solid dispersion of tacrolimus in a vehicle further comprising a stabilizing agent capable of providing a pH below 7 in the composition, as measured after re-dispersion in water, and preventing or reducing the formation upon storage of major degradation products of tacrolimus, in particular the 8-epitacrolimus.

Classes IPC  ?

  • A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
  • A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
  • A61K 9/20 - Pilules, pastilles ou comprimés

26.

Miscellaneous Design

      
Numéro d'application 1179846
Statut Enregistrée
Date de dépôt 2013-08-15
Date d'enregistrement 2013-08-15
Propriétaire Veloxis Pharmaceuticals, Inc. (USA)
Classes de Nice  ?
  • 05 - Produits pharmaceutiques, vétérinaires et hygièniques
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.

Produits et services

Pharmaceutical preparations, including immunotherapeutic and immunosuppressive preparations for medical use for treatment of transplantation patients; medical preparations and drug delivery systems, pharmaceutical modified release systems, and controlled release systems, comprised of tablets, granules; pills, sachets, powders, capsules, all of the above inter alia for use in the treatment of mental and physical disorders, traumas and emergencies, addictions, aging, allergy/immunology, burns, diseases of the heart and blood vessels, dental and gum diseases, skin diseases, nutritional and dietary diseases, diseases of the endocrinological system and pancreatic diseases, diabetes, epidemical diseases, diseases and afflictions of the gastroenterological system, diseases of the blood, infectious diseases, neurological diseases, nephrological diseases, diseases in the obstetrical and gynecological field, cancer, ophthalmological diseases, diseases and afflictions affecting the bones, joints, cartilage material and muscles, diseases and afflictions of the ear, nose and throat, diseases and afflictions in the psychiatric field, pulmonological diseases and afflictions, rheumatism, urological diseases and afflictions and generalised pain; veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. Scientific and technological services as well as research and design in connection therewith, including within the medical, pharmaceutical, biotechnical and bacteriological areas and providing consultation and information relating thereto; conducting of tests regarding medical applications; packaging design for others; designing and development of medical equipment; designing pharmaceutical medical preparations; development of pharmaceutical formulations; design and development of granulation technology and tablet technology and providing consultation and information thereto; materials testing for the pharmaceutical and medical industries; industrial analysis and research; design and development of computer hardware and computer software. Medical services; medical and pharmaceutical assistance and consultation; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.

27.

ENVARSUS

      
Numéro d'application 1168212
Statut Enregistrée
Date de dépôt 2013-02-07
Date d'enregistrement 2013-02-07
Propriétaire Veloxis Pharmaceuticals, Inc. (USA)
Classes de Nice  ?
  • 05 - Produits pharmaceutiques, vétérinaires et hygièniques
  • 40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.

Produits et services

Pharmaceutical preparations, including immunotherapeutic and immunosuppressive preparations for medical use for treatment of transplantation patients; medical preparations and drug delivery systems, pharmaceutical modified release systems, and controlled release systems, comprised of tablets, granules, pills, sachets, powders, capsules, all of the above i.a. for use in the treatment of mental and physical disorders, traumas and emergencies, addictions, aging, allergy/immunology, burns, diseases of the heart and blood vessels, dental and gum diseases, skin diseases, nutritional and dietary diseases, diseases of the endocrinological system and pancreatic diseases, diabetes, epidemical diseases, diseases and afflictions of the gastroenterological system, diseases of the blood, infectious diseases, neurological diseases, nephrological diseases, diseases in the obstetrical and gynecological field, cancer, ophthalmological diseases, diseases and afflictions affecting the bones, joints, cartilage material and muscles, diseases and afflictions of the ear, nose and throat, diseases and afflictions in the psychiatric field, pulmonological diseases and afflictions, rheumatism, urological diseases and afflictions and generalised pain; veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. Treatment of materials, including milling, grinding, mixing, compressing, and melting of pharmaceutical, medicinal, biotechnical and bacteriological substances, preparations, formulations and solutions, for use in the pharmaceutical and medical industries. Scientific and technological services as well as research and design in connection therewith, including within the medical, pharmaceutical, biotechnical and bacteriological areas and providing consultation and information relating thereto; conducting of tests regarding medical applications; packaging design for others; designing and development of medical equipment; designing pharmaceutical medical preparations; development of pharmaceutical formulations; design and development of granulation technology and tablet technology and providing consultation and information thereto; materials testing for the pharmaceutical and medical industries; industrial analysis and research; design and development of computer hardware and computer software. Medical services; medical and pharmaceutical assistance and consultation; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.

28.

ENVARSUS

      
Numéro de série 79133181
Statut Enregistrée
Date de dépôt 2013-02-07
Date d'enregistrement 2013-12-31
Propriétaire Veloxis Pharmaceuticals, Inc. (USA)
Classes de Nice  ?
  • 40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
  • 05 - Produits pharmaceutiques, vétérinaires et hygièniques
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.

Produits et services

[ Treatment of materials, namely, milling, grinding, mixing, compressing, and melting of pharmaceutical, medicinal, biotechnical and bacteriological substances, preparations, formulations and solutions, for use in the pharmaceutical and medical industries ] Pharmaceutical preparations, namely, immunotherapeutic and immunosuppressive preparations for medical use for treatment of transplantation patients; medical preparations and drug delivery systems, pharmaceutical modified release systems, and controlled release systems, comprised of tablets, granules, pills, sachets, powders, capsules, all of the above for use in the treatment of mental and physical disorders, traumas and emergencies, addictions, aging, allergy and immunology, burns, diseases of the heart and blood vessels, dental and gum diseases, skin diseases, nutritional and dietary diseases, diseases of the endocrinological system and pancreatic diseases, diabetes, epidemical diseases, diseases and afflictions of the gastroenterological system, diseases of the blood, infectious diseases, neurological diseases, nephrological diseases, diseases in the obstetrical and gynecological field, cancer, ophthalmological diseases, diseases and afflictions affecting the bones, joints, cartilage material and muscles, diseases and afflictions of the ear, nose and throat, diseases and afflictions in the psychiatric field, pulmonological diseases and afflictions, rheumatism, urological diseases and afflictions and generalised pain [ Scientific and technological services, namely, clinical testing and technology transfer services as well as research and design in connection therewith, namely, within the medical, pharmaceutical, biotechnical and bacteriological areas and providing scientific consultation and information relating thereto; conducting of tests regarding medical applications; packaging design for others; designing and development of medical equipment; designing pharmaceutical medical preparations; development of pharmaceutical formulations; design and development of granulation technology and tablet technology and providing consultation and information thereto; materials testing for the pharmaceutical and medical industries ] [ Medical services; medical and pharmaceutical assistance and consultation, namely, medical and pharmaceutical information services, namely, providing medical and scientific research information in the field of pharmaceuticals ]

29.

ENVARSUS

      
Numéro d'application 011135894
Statut Enregistrée
Date de dépôt 2012-08-23
Date d'enregistrement 2013-01-22
Propriétaire Veloxis Pharmaceuticals, Inc. (USA)
Classes de Nice  ?
  • 05 - Produits pharmaceutiques, vétérinaires et hygièniques
  • 40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.

Produits et services

Pharmaceutical preparations, including immunotherapeutic and immunosuppressive preparations for medical use for treatment of transplantation patients; medical preparations and drug delivery systems, pharmaceutical modified release systems, and controlled release systems, comprised of tablets, granules, pills, sachets, powders, capsules, solutions or fluids, all of the above ia for use in the treatment of mental and physical disorders, traumas and emergencies, addictions, aging, allergy/immunology, burns, diseases of the heart and blood vessels, dental and gum diseases, skin diseases, nutritional and dietary diseases, diseases of the endocrinological system and pancreatic diseases, diabetes, epidemical diseases, diseases and afflictions of the gastroenterological system, diseases of the blood, infectious diseases, neurological diseases, nephrological diseases, diseases in the obstetrical and gynaecological field, cancer, ophthalmological diseases, diseases and afflictions affecting the bones, joints, cartilage material and muscles, diseases and afflictions of the ear, nose and throat, diseases and afflictions in the psychiatric field, pulmonological diseases and afflictions, rheumatism, urological diseases and afflictions and generalised pain; veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. Treatment of materials, including milling, grinding, mixing, compressing, and melting of pharmaceutical, medicinal, biotechnical and bacteriological substances, preparations, formulations and solutions, for use in the pharmaceutical and medical industries. Scientific and technological services as well as research and design in connection therewith, including within the medical, pharmaceutical, biotechnical and bacteriological areas and providing consultation and information relating thereto; conducting of tests regarding medical applications; packaging design for others; designing and development of medical equipment; designing pharmaceutical medical preparations; development of pharmaceutical formulations; design and development of granulation technology and tablet technology and providing consultation and information thereto; materials testing for the pharmaceutical and medical industries; industrial analysis and research; design and development of computer hardware and computer software. Medical services; medical and pharmaceutical assistance and consultation, including medical and pharmaceutical information services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.

30.

Solid dosage form comprising a fibrate

      
Numéro d'application 13315030
Numéro de brevet 08481078
Statut Délivré - en vigueur
Date de dépôt 2011-12-08
Date de la première publication 2012-08-02
Date d'octroi 2013-07-09
Propriétaire
  • VELOXIS PHARMACEUTICALS INC. (USA)
  • VELOXIS PHARMACEUTICALS INC. (USA)
Inventeur(s)
  • Holm, Per
  • Norling, Tomas

Abrégé

The invention provides stable, solid dosage forms and pharmaceutical compositions in particulate form comprising a fibrate, for example fenofibrate, dissolved in an non-aqueous vehicle in order to ensure improved bioavailability of the active ingredient upon oral administration relative to known fibrate formulations.

Classes IPC  ?

  • A61K 9/20 - Pilules, pastilles ou comprimés

31.

Tacrolimus for improved treatment of transplant patients

      
Numéro d'application 13167420
Numéro de brevet 08664239
Statut Délivré - en vigueur
Date de dépôt 2011-06-23
Date de la première publication 2012-02-02
Date d'octroi 2014-03-04
Propriétaire VELOXIS PHARMACEUTICALS INC. (USA)
Inventeur(s)
  • Gordon, Robert D.
  • Holm, Per
  • Lademann, Anne-Marie
  • Norling, Tomas

Abrégé

An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.

Classes IPC  ?

  • A61K 31/44 - Pyridines non condenséesLeurs dérivés hydrogénés
  • A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine

32.

Veloxis PHARMACEUTICALS

      
Numéro d'application 1093252
Statut Enregistrée
Date de dépôt 2011-07-07
Date d'enregistrement 2011-07-07
Propriétaire Veloxis Pharmaceuticals, Inc. (USA)
Classes de Nice  ?
  • 05 - Produits pharmaceutiques, vétérinaires et hygièniques
  • 40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
  • 41 - Éducation, divertissements, activités sportives et culturelles
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
  • 45 - Services juridiques; services de sécurité; services personnels pour individus

Produits et services

Pharmaceutical preparations, including immunotherapeutic and immunosuppressive preparations for medical use for treatment of transplantation patients; medical preparations and drug delivery systems, pharmaceutical modified release systems, and controlled release systems, comprised of tablets, granules, pills, sachets, powders, capsules, solutions or fluids, all of the above i.a. for use in the treatment of mental and physical disorders, traumas and emergencies, addictions, aging, allergy/immunology, burns, diseases of the heart and blood vessels, dental and gum diseases, skin diseases, nutritional and dietary diseases, diseases of the endocrinological system and pancreatic diseases, diabetes, epidemical diseases, diseases and afflictions of the gastroenterological system, diseases of the blood, infectious diseases, neurological diseases, nephrological diseases, diseases in the obstetrical and gynecological field, cancer, ophthalmological diseases, diseases and afflictions affecting the bones, joints, cartilage material and muscles, diseases and afflictions of the ear, nose and throat, diseases and afflictions in the psychiatric field, pulmonological diseases and afflictions, rheumatism, urological diseases and afflictions and generalised pain; veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. Treatment of materials, including milling, grinding, mixing, compressing, and melting of pharmaceutical, medicinal, biotechnical and bacteriological substances, preparations, formulations and solutions, for use in the pharmaceutical and medical industries. Education and training services, including arranging and conducting of seminars, workshops, conferences, lectures and congresses, all in the medical, chemical and pharmaceutical fields. Scientific and technological services as well as research and design in connection therewith, including within the medical, pharmaceutical, biotechnical and bacteriological areas and providing consultation and information relating thereto; conducting of tests regarding medical applications; packaging design for others; designing and development of medical equipment; designing pharmaceutical medical preparations; development of pharmaceutical formulations; design and development of granulation technology and tablet technology and providing consultation and information thereto; materials testing for the pharmaceutical and medical industries; industrial analysis and research; design and development of computer hardware and computer software. Medical services; medical and pharmaceutical assistance and consultation, including medical and pharmaceutical information services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. Legal services; consultancy services regarding intellectual property; licensing of intellectual property.

33.

FENOGLIDE

      
Numéro d'application 1091569
Statut Enregistrée
Date de dépôt 2011-08-30
Date d'enregistrement 2011-08-30
Propriétaire Veloxis Pharmaceuticals, Inc. (USA)
Classes de Nice  ? 05 - Produits pharmaceutiques, vétérinaires et hygièniques

Produits et services

Pharmaceutical and veterinary medical preparations, including for physical and mental diseases.

34.

VELOXIS PHARMACEUTICALS

      
Numéro d'application 1088877
Statut Enregistrée
Date de dépôt 2011-07-07
Date d'enregistrement 2011-07-07
Propriétaire Veloxis Pharmaceuticals, Inc. (USA)
Classes de Nice  ?
  • 05 - Produits pharmaceutiques, vétérinaires et hygièniques
  • 40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
  • 41 - Éducation, divertissements, activités sportives et culturelles
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
  • 45 - Services juridiques; services de sécurité; services personnels pour individus

Produits et services

Pharmaceutical preparations, including immunotherapeutic and immunosuppressive preparations for medical use for treatment of transplantation patients; medical preparations and drug delivery systems, pharmaceutical modified release systems, and controlled release systems, comprised of tablets, granules, pills, sachets, powders, capsules, solutions or fluids, all of the above i.a, for use in the treatment of mental and physical disorders, traumas and emergencies, addictions, aging, allergy/ immunology, burns, diseases of the heart and blood vessels, dental and gum diseases, skin diseases, nutritional and dietary diseases, diseases of the endocrinological system and pancreatic diseases, diabetes, epidemical diseases, diseases and afflictions of the gastroenterological system, diseases of the blood, infectious diseases, neurological diseases, nephrological diseases, diseases in the obstetrical and gynecological field, cancer, ophthalmological diseases, diseases and afflictions affecting the bones, joints, cartilage material and muscles, diseases and afflictions of the ear, nose and throat, diseases and afflictions in the psychiatric field, pulmonological diseases and afflictions, rheumatism, urological diseases and afflictions and generalized pain; veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. Treatment of materials, including milling, grinding, mixing, compressing, and melting of pharmaceutical, medicinal, biotechnical and bacteriological substances, preparations, formulations and solutions, for use in the pharmaceutical and medical industries. Education and training services, including arranging and conducting of seminars, workshops, conferences, lectures and congresses, all in the medical, chemical and pharmaceutical fields. Scientific and technological services as well as research and design in connection therewith, including within the medical, pharmaceutical, biotechnical and bacteriological areas and providing consultation and information relating thereto; conducting of tests regarding medical applications; packaging design for others; designing and development of medical equipment; designing pharmaceutical medical preparations; development of pharmaceutical formulations; design and development of granulation technology and tablet technology and providing consultation and information thereto; materials testing for the pharmaceutical and medical industries; industrial analysis and research; design and development of computer hardware and computer software. Medical services; medical and pharmaceutical assistance and consultation, including medical and pharmaceutical information services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. Legal services; consultancy services regarding intellectual property; licensing of intellectual property.

35.

VELOXIS PHARMACEUTICALS

      
Numéro de série 79101875
Statut Enregistrée
Date de dépôt 2011-07-07
Date d'enregistrement 2013-06-11
Propriétaire Veloxis Pharmaceuticals, Inc. ()
Classes de Nice  ?
  • 05 - Produits pharmaceutiques, vétérinaires et hygièniques
  • 40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
  • 41 - Éducation, divertissements, activités sportives et culturelles
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
  • 45 - Services juridiques; services de sécurité; services personnels pour individus

Produits et services

Pharmaceutical preparations, namely, immunotherapeutic and immunosuppressive preparations for medical use for treatment of transplant patients; pharmaceutical preparations and drug delivery systems, pharmaceutical modified drug delivery release systems, and pharmaceutical controlled drug delivery release systems, comprised of tablets, granules, pills, sachets, powders, capsules, solutions or fluids, all of the above for use in the treatment of mental and physical disorders, emergencies and traumas, aging, namely, Alzheimer's disease, arthritis, shock, immune system diseases, allergies and burns, diseases of the heart and blood vessels, dental and gum diseases, skin diseases, nutritional and dietary disorders, diseases of the endocrinological system and pancreatic diseases, diabetes, epidemical diseases, diseases and afflictions of the gastroenterological system, diseases of the blood, infectious diseases, neurological diseases, nephrological diseases, gynecological diseases, cancer, ophthalmological diseases, diseases and afflictions affecting the bones, joints, cartilage material and muscles, diseases and afflictions of the ear, nose and throat, psychiatric diseases and disorders, pulmonological diseases and afflictions, rheumatism, urological diseases and afflictions and generalized pain [ Treatment of materials, namely, milling, grinding, mixing, compressing, and melting of pharmaceutical, medicinal, biotechnical and bacteriological substances, preparations, formulations and solutions, for use in the pharmaceutical and medical industries ] Education and training services, namely, arranging and conducting of seminars, workshops, conferences, lectures and congresses, all in the medical, chemical and pharmaceutical fields Scientific and technological services, namely, scientific research, analysis and testing in the field of medical science, pharmacology, biotechnology and bacteriological areas and providing consultation and information relating thereto; design of drug delivery systems for medical use; conducting of tests regarding medical applications; packaging design for others; designing and development of medical equipment; designing pharmaceutical medical preparations; development of pharmaceutical formulations; design and development of granulation technology and tablet technology and providing consultation and information thereto; materials testing for the pharmaceutical and medical industries Medical and pharmaceutical assistance and consultation, namely, medical and pharmaceutical consultation, pharmaceutical advice, providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals [ Consulting in the field of intellectual property licensing; licensing of intellectual property ]

36.

VELOXIS PHARMACEUTICALS

      
Numéro de série 79103548
Statut Enregistrée
Date de dépôt 2011-07-07
Date d'enregistrement 2012-09-25
Propriétaire Veloxis Pharmaceuticals, Inc. ()
Classes de Nice  ?
  • 05 - Produits pharmaceutiques, vétérinaires et hygièniques
  • 40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
  • 41 - Éducation, divertissements, activités sportives et culturelles
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
  • 45 - Services juridiques; services de sécurité; services personnels pour individus

Produits et services

Pharmaceutical preparations, namely, immunotherapeutic and immunosuppressive preparations for medical use for treatment of transplant patients; pharmaceutical preparations and drug delivery systems, pharmaceutical modified release systems, and pharmaceutical controlled release systems, comprised of tablets, granules, pills, sachets, powders, capsules, solutions or fluids, all of the above for use in the treatment of [ mental and ] physical disorders, emergencies and traumas, [ aging, allergy and immunology, ] burns, diseases of the heart and blood vessels, [ dental and gum diseases, skin diseases, nutritional and dietary diseases, diseases of the endocrinological system and pancreatic diseases, diabetes, epidemical diseases, diseases and afflictions of the gastroenterological system, diseases of the blood, infectious diseases, ] neurological diseases, [ nephrological diseases, diseases in the obstetrical and gynecological field, ] cancer [, ophthalmological diseases, diseases and afflictions affecting the bones, joints, cartilage material and muscles, diseases and afflictions of the ear, nose and throat, diseases and afflictions in the psychiatric field, pulmonological diseases and afflictions, rheumatism, urological diseases and afflictions and generalized pain ] [ Treatment of materials, namely, milling, grinding, mixing, compressing, and melting of pharmaceutical, medicinal, biotechnical and bacteriological substances, preparations, formulations and solutions, for use in the pharmaceutical and medical industries ] Education and training services, namely, arranging and conducting of seminars, workshops, conferences, lectures and congresses, all in the medical, chemical and pharmaceutical fields Scientific and technological services, namely, scientific research, analysis and testing in the field of medical science, pharmacology, biotechnology and bacteriological areas and providing consultation and information relating thereto; design of drug delivery systems for medical use; conducting of tests regarding medical applications; packaging design for others; designing and development of medical equipment; designing pharmaceutical medical preparations; development of pharmaceutical formulations; design and development of granulation technology and tablet technology and providing consultation and information thereto; materials testing for the pharmaceutical and medical industries Medical and pharmaceutical assistance and consultation, namely, medical and pharmaceutical information services, namely, providing medical and scientific research information in the field of pharmaceuticals [ Consultancy services regarding intellectual property; licensing of intellectual property; medical and pharmaceutical assistance and consultation, including medical and pharmaceutical information services ]

37.

Tacrolimus for improved treatment of transplant patients

      
Numéro d'application 12499034
Numéro de brevet 08685998
Statut Délivré - en vigueur
Date de dépôt 2009-07-07
Date de la première publication 2010-04-29
Date d'octroi 2014-04-01
Propriétaire VELOXIS PHARMACEUTICALS INC. (USA)
Inventeur(s)
  • Gordon, Robert D.
  • Holm, Per
  • Lademann, Anne-Marie
  • Norling, Tomas

Abrégé

An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.

Classes IPC  ?

  • A61K 31/44 - Pyridines non condenséesLeurs dérivés hydrogénés
  • A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine

38.

Tablet comprising a fibrate

      
Numéro d'application 11449918
Numéro de brevet 09173847
Statut Délivré - en vigueur
Date de dépôt 2006-06-09
Date de la première publication 2007-02-01
Date d'octroi 2015-11-03
Propriétaire
  • VELOXIS PHARMACEUTICALS INC. (USA)
  • VELOXIS PHARMACEUTICALS INC. (USA)
Inventeur(s)
  • Holm, Per
  • Norling, Tomas

Abrégé

Stable tablets and pharmaceutical compositions in particulate form comprising a fibrate, for example fenofibrate, dissolved or dispersed in an non-aqueous vehicle with improved bioavailability, thereby eliminating the food effect so that the tablet or composition can be administered to a patient irrespective of being in fed or fasted state.

Classes IPC  ?

  • A61K 9/20 - Pilules, pastilles ou comprimés
  • A61K 9/16 - AgglomérésGranulésMicrobilles
  • A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique

39.

Modified release compositions comprising tacrolimus

      
Numéro d'application 10569862
Numéro de brevet 08591946
Statut Délivré - en vigueur
Date de dépôt 2004-08-30
Date de la première publication 2006-12-21
Date d'octroi 2013-11-26
Propriétaire VELOXIS PHARMACEUTICALS INC. (USA)
Inventeur(s) Holm, Per

Abrégé

A modified release composition comprising tacrolimus releases less than 20% w/w of the active ingredient within 0.5 hours when subjected to an in vitro dissolution test using USP Paddle method and using 0.1 N HCl as dissolution medium and has increased bioavailability by effectively reducing or even avoiding the effects of CYP3A4 metabolism. The modified composition may be coated with an enteric coating; and/or may comprise a solid dispersion or a solid solution of tacrolimus in a hydrophilic or water-miscible vehicle and one or more modifying release agents; and/or may comprise a solid dispersion or a solid solution of tacrolimus in an amphiphilic or hydrophobic vehicle and optionally one or more modifying release agents.

Classes IPC  ?

  • A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres

40.

MELTDOSE

      
Numéro de série 78219715
Statut Enregistrée
Date de dépôt 2003-02-27
Date d'enregistrement 2005-06-07
Propriétaire VELOXIS PHARMACEUTICALS, INC. ()
Classes de Nice  ?
  • 05 - Produits pharmaceutiques, vétérinaires et hygièniques
  • 41 - Éducation, divertissements, activités sportives et culturelles
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception

Produits et services

[ Pharmaceutical preparations; medical preparations; and drug delivery systems, ] pharmaceutical modified release systems, and controlled release systems, comprised of tablets, [ granules, pills, sachets, powders, and capsules; ] all of the above for use in the treatment of [ mental and physical disorders, traumas and emergencies, addictions, aging, allergy/immunology, burns, ] diseases of [ the heart and ] blood vessels, [ dental and gum diseases, skin diseases, nutritional and dietary diseases, diseases of the endocrinological system and pancreatic diseases, diabetes, epidemical diseases, diseases and afflictions of the gastroenterological system, ] diseases of the blood, [ infectious diseases, neurological diseases, nephrological diseases, diseases in the obstetrical- and gynecological field, cancer, ophthalmological diseases, diseases and afflictions affecting the bones, joints, cartilage material and muscles, diseases and afflictions of the ear, nose and throat, diseases and afflictions in the psychiatric field, pulmonological diseases and afflictions, rheumatism, urological diseases and afflictions and generalised pain ] [ Educational training services, namely, arranging and conducting of seminars, workshops, conferences, lectures and congresses, all in the medical, chemical, and pharmaceutical fields ] [ Scientific research, namely, bacteriological research, biological research, biotechnological research, scientific research services for medical purposes and scientific research consultation; research and development for new products for others; industrial design services; pharmaceutical and medical consultation regarding pharmaceutical drug development services; cosmetic research for others; design services for others in the field of medical packaging and equipment; medical research; medical and scientific research, namely, conducting clinical trials, namely, testing of medical substances and testing of medical applications; pharmaceutical drug development services, namely, development of medical applications, drug design, drug formulation, pharmaceutical formulation, and development of pharmaceutical formulations and consultation regarding pharmaceutical formulation; ] development of drug delivery systems for others, namely, development of solid dosage forms, pharmaceutical controlled release systems, modified release systems and pharmaceutical modified release systems and consultation related thereto; [ pharmaceutical drug development services, namely, development of mixing technology, development of particulate material, development of particulate material mixing technology, development of granulate technology, development of tabletting technology, and consultation related thereto ]

41.

MELTDOSE

      
Numéro d'application 003071693
Statut Enregistrée
Date de dépôt 2003-02-26
Date d'enregistrement 2004-09-07
Propriétaire Veloxis Pharmaceuticals, Inc. (USA)
Classes de Nice  ?
  • 05 - Produits pharmaceutiques, vétérinaires et hygièniques
  • 40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
  • 41 - Éducation, divertissements, activités sportives et culturelles
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception

Produits et services

Pharmaceutical and veterinary preparations, including for physical and mental illnesses, sanitary preparations for medical purposes, dietetic substances adapted for medical use, disinfectants; fungicides, herbicides. Treatment of materials. Education; arrangement of and conducting seminars, workshops, conferences, lectures and congresses. Scientific research within the medical, pharmaceutical and bacteriological area including consultancy and information relating thereto, conducting of tests regarding medical applications; packaging design, designing and development of medical equipment, designing pharmaceutical and medical preparations, preparation of pharmaceutical formulations, design and development of granulation technology and tablet technology including consultancy and information relating thereto.